Drug, bio-affecting and body treating compositions inventions 01/08

20080025913 - Novel anti-dc-sign antibodies: Antibodies to DC-SIGN are disclosed which are capable of modulating the interaction of dendritic cells and T cells. In some embodiments, the antibodies inhibit the interaction of dendritic cells and T cells. In other embodiments, the antibodies are combined with peptides which are internalized in dendritic cells and presented to... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080025915 - Technetium-and rhenium-bis (heteroaryl) complexes, and methods of use thereof: One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of... Agent: Foley & Lardner LLP

20080025916 - Tailored treatment suitable for different forms of mastocytosis: The present invention relates to a method for a tailored treatment of mastocytosis comprising a) assessing whether or not a c-kit mutation at position 816 is detected in a sample of a patient and b) administering a specific 816 mutant c-kit inhibitor in case a mutation is detected in step... Agent: Foley And Lardner LLP Suite 500

20080025925 - Dental bleaching compositions having long-term rheological stability and devices, kits and methods that utilize such compositions: Dental bleaching compositions include a dental bleaching agent, a generally linear high molecular weight (i.e., greater than about 500,000) polyvinyl pyrrolidone (PVP) and/or polyethylene oxide (PEO) tissue adhesion agent included in amount that imparts a high level of adhesiveness, a rheology-modifying agent such as fumed silica or fumed alumina that... Agent: Workman Nydegger

20080025926 - Oral care formulations with hydrogen peroxide and lycopene: A toothpaste formulation is disclosed which comprises hydrogen peroxide; and cetylpyridinium chloride, and wherein the hydrogen peroxide and the cetylpyridinium chloride have been combined in the toothpaste formulation for not more than about seven minutes prior to administration to an individual. A mouth rinse formulation is disclosed which comprises hydrogen... Agent: Buchanan, Ingersoll & Rooney PC

20080025930 - Anti-aging compositions comprising menyanthes trifoliata leaf extracts and methods of use thereof: An anti-aging composition comprising a skin-beneficial amount of actives identified in Menyanthes trifoliata leaf, wherein the actives are inhibitors of one or more of MMP-1, 2 and 9 and/or scavengers of peroxynitrite. Also disclosed are methods of using such a composition, which include treating the skin for signs of chronological... Agent: The Estee Lauder Cos, Inc

20080025929 - Topical formulations for the treatment of skin conditions: The invention features compositions for topical administration of an oxidatively transformed carotenoid or 2-methyl-6-oxo-2,4-heptadienal and methods of treating skin conditions therewith.... Agent: Clark & Elbing LLP

20080025934 - Cosmetic composition combining a copolymer, a non-volatile oil and a glossy oil: A cosmetic composition includes, in a physiologically acceptable medium, at least: one copolymer containing at least alkyl methacrylate, alkyl acrylate and acrylic acid monomers; one non-volatile oil having a hydrocarbon-based chain containing at least 16 carbon atoms and having a molar mass of less than 650 g/mol; and one glossy... Agent: Oliff & Berridge, PLC

20080025941 - Compositions containing quaternary ammonium compounds: This invention relates to compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, characterized in that said composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which... Agent: Young & Thompson

20080025943 - Modified two-component gelation systems, methods of use and methods of manufacture: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first... Agent: Blakely Sokoloff Taylor & Zafman

20080025944 - Combination therapy for immunostimulation: The present invention relates to a method for immunostimulation in a mammal, which comprises a. administration of at least one mRNA containing a region which codes for at least one antigen of a pathogen or at least one tumour antigen, and b. administration of at least one cytokine, at least... Agent: Connolly Bove Lodge & Hutz LLP

20080025945 - Use of il-6 in liver injury: The invention relates to the use of IL-6 in liver cirrhosis.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080025948 - Methods of treatment using interferon-tau: Methods of modulating cytokine levels in a human subject by administering interferon-tau (IFNτ) are described. More specifically, a method of up-regulating the interleukin 10 (IL-10) level in patients afflicted with a condition that responds to treatment by having an increased blood IL-10 level, such as an autoimmune condition, a viral... Agent: Perkins Coie LLP

20080025949 - Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives: This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous... Agent: Rashida A. Karmali

20080025950 - Modified macromolescules and associated methods of synthesis and use: Described herein are compounds such as macromolecules that have been modified in order to facilitate crosslinking by introduction of at least one hydrazide-reactive group and/or aminooxy-reactive group, and methods of making and using thereof for scar-free wound healing, for delivering bioactive agents or living cells, for preventing adhesion after a... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080025951 - Cytokine antagonist molecules: This invention relates to novel uses of a protein sequence (INSP052EC), herein identified as an immunoglobulin domain-containing cell surface recognition, in the diagnosis, prevention and treatment of diseases, in particular those related to the excessive expression and/or secretion of cytokines.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080025957 - Stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them: The present invention relates to stem cells suitable for transplantation and to methods for their preparation.... Agent: Marshall, Gerstein & Borun LLP

20080025954 - Use of gingival fibroblasts for vascular cell therapy: The invention relates to the use of gingival fibroblasts for obtaining a cellular composition for treating arterial-remodelling pathology, for example an aneurysm, post-cryoplasty stenosis and restenosis, an aortic dissection or atherosclerosis.... Agent: Alston & Bird LLP

20080025953 - Vigor enhancement of animals via administration of stem cells: Disclosed herein are methods for increasing the vigor of nonhuman vertebrates utilizing stem cells. Unlike methods designed to treat disease conditions, the methods exemplified herein teach the utilization of stem cells for increasing vigor in animals not necessarily for the purpose of treating a disease, but can include application to... Agent: Beusse Wolter Sanks Mora & Maire

20080025961 - Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory: The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080025966 - Methods and compositions for the treatment of gastrointestinal disorders: The use of chymotrypsin inhibitors for treating various disorders, including IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic... Agent: Fish & Richardson PC

20080025914 - Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug: The present invention relates to the treatment of immune system abnormalities that can be found in lethal human cancers and also in the progressive Human Immunodeficiency Virus Type 1 (HIV-1) infections and provides medicaments to correct abnormalities in a subject with cancer or HIV-1-infected subjects, in order to allow the... Agent: Dla Piper US LLP

20080025917 - Methods for modulating formation and progression of cellulite: This invention provides methods and compositions for modulating the formation and/or progression of cellulite and other skin disorders in a subject.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080025918 - Invisible light fluorescent platelets for intraoperative detection of vascular thrombosis: This invention relates to methods, kits, and compositions for intraoperative detection of aggregates of platelets, e.g., associated with vascular thrombosis, using invisible light fluorophore (IRF)-loaded platelets.... Agent: Fish & Richardson PC

20080025919 - Benzoylguanidine salt and hydrates thereof: 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride and its hydrates, processes for preparing this benzoylguanidine salt and its hydrates, pharmaceutical compositions containing this benzoylguanidine salt and its hydrates, and its use in treating diseases, particularly those in which inhibition of the cellular Na+/H+ exchange is of therapeutic benefit.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080025921 - Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease: This invention provides the methodology and agents for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide for the release of normally retained proteins from the endoplasmic reticulum. The present... Agent: Choate, Hall & Stewart LLP

20080025920 - Methods of treating hot flashes with formulations for transdermal or transmucosal application: The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about... Agent: Winston & Strawn LLP Patent Department

20080025922 - Bronzer composition: Bronzer compositions are provided. They comprise (a) water, (b) at least one water-soluble dye; and (c) at least one water-dispersible or water-soluble film-forming polymer. Optionally, a self-tanning agent such as 1,3-dihydroxyacetone may be present.... Agent: Philip S. Johnson Johnson & Johnson

20080025923 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025924 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025927 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025928 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025931 - Cosmetic method for limiting age-related hollowing of the face: Disclosed herein is a cosmetic method for remodelling the face and/or limiting age-related hollowing of the face, by applying to the skin of the face and/or the neck, a composition containing, in a physiologically acceptable medium, at least one extract of a non-fruiting non-photosynthetic filamentous bacterium.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080025932 - Skin care compositions containing a sugar amine: Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025933 - Elastic cationic polyurethanes: The invention concerns novel cationic polyurethanes with elastic character, that is having immediate recovery ranging between 5% and 95%, consisting essentially (a1) of cationic units derived from at least a tertiary amine having at least two functions reactive to labile hydrogen, said tertiary amine being at least partly neutralised, (a2)... Agent: Nixon & Vanderhye, PC

20080025935 - Inhibition of sweat malodor: The present invention relates to a method for screening compounds having the ability to prevent, treat or reduce malodor development on body surfaces. In particular, the method allows to efficiently screen for compound having the ability of preventing sweat malodor development caused by volatile sulfur compounds (VSCs). The present invention... Agent: Winston & Strawn LLP Patent Department

20080025937 - Method and composition for permanently shaping hair: or the salt thereof, wherein R1 is a straight chain alkyl residue with about 3 to about 6 carbon atoms or a straight chain hydroxyalkyl residue with about 3 to about 6 carbon atoms, R2 and R3 are hydrogen or straight chain alkyl residues with about 1 to about 3... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025936 - Use of natural zein for improving the condition of hair and agent therefor: The object of the present invention is the use of natural zein for improving the condition of hair, preferably for hardening, strengthening, restructuring or increasing the luster, volume or combability of human hair.... Agent: Striker, Striker & Stenby

20080025938 - Method and composition for permanently shaping hair: (ii) about 0.1% by weight to about 20% by weight of at least one further hair keratin reducing agent selected from the group consisting of thioglycolic acid, thiolactic acid, 3-mercaptopropionic acid, 2-hydroxy-3-mercaptopropionic acid, cysteine, cysteamine, alkyl- or acylcysteamine with about 1 to about 4 carbon atoms in the alkyl residue,... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025939 - Method and composition for permanently shaping hair: (ii) about 0.1% by weight to about 15% by weight of at least one alkalizing agent selected from the group consisting of lithium hydroxide, earth alkali metal hydroxides; hydroxyalkyl substituted amines with about 1 to about 3 alkyl residues comprising about 1 to about 4 carbon atom in the alkyl... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080025940 - Administration of 3-sulfanylpropanamide compounds for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof: are useful for caring for and/or making up keratin fibers, especially human keratin fibers, to induce and/or stimulate the growth, to stop the loss and/or to increase the density thereof, and/or to improve the appearance and/or to reduce the canities thereof, and/or to stimulate the pigmentation and/or to limit the... Agent: Buchanan, Ingersoll & Rooney PC

20080025942 - High concentration single phase glycol aerosol air sanitizer with dimethyl ether propellant/solvent: Improved single-phase aerosol spray air sanitizers are disclosed. The preferred active ingredient for the air sanitization is a high concentration of triethylene glycol (TEG), made possible in the single-phase aerosol formulation by the use of dimethyl ether (DME) as a propellant. The combination of TEG and DME enables high concentrations... Agent: S.c. Johnson & Son, Inc.

20080025946 - Interleukin 21 and tyrosine kinase inhibitor combination therapy: The present invention provides methods for use of IL-21 in combination with a tyrosine kinase inhibitor (TKI) in treatment of diseases in which inhibition of phosphorylation via TK inhibition and modulation of immune function play a clinically beneficial role. These diseases include, but are not limited to, cancers, such as... Agent: Zymogenetics, Inc. Intellectual Property Department

20080025947 - Methods for enhancing the efficacy of il-2 mediated immune responses: Methods directed to enhancing the effectiveness of IL-2 in stimulating the immune system is disclosed. According to one method, an antagonist directed against the CD25 subunit of the high-affinity IL-2 receptor complex is administered in conjunction with IL-2. The CD25 antagonist may be an anti-CD25 antibody. According to another method,... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20080025952 - Methods for targeted deliver of genetic material to the liver: The present invention provides methods for enhanced delivery of various therapeutic agents, such as gene therapy agents, to the vasculature of a target organ in a mammalian subject. The methods for targeted gene therapy in the mammalian liver as a whole, or in a single hepatic lobe, are disclosed. The... Agent: Genzyme Corporation Legal Department

20080025958 - Cell-based rna interference and related methods and compositions: This invention provides barcoded shRNA libraries and methods of using same.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080025956 - Blood vessel formation from endothelial colony forming cells: Methods and compositions to form fully functional blood vessels in vivo using endothelial colony forming cells (ECFCs) are disclosed. Culturing ECFCs in a support material results in association of ECFCs in vitro and formation of blood vessels in vivo upon implantation. Direct administration of cultured ECFCs form blood vessels in... Agent: Barnes & Thornburg LLP

20080025955 - Method of producing vascular endothelial cells from primate embryonic stem cells: To provide a method for differentiating primate embryonic stem cells into vascular endothelial cells, and a technique using the method. A method for differentiating primate embryonic stem cells into early developmental vascular endothelial cells comprising differentiating primate embryonic stem cells into vascular endothelial cell parker-positive cell population; the early developmental... Agent: Birch Stewart Kolasch & Birch

20080025959 - Permeability of blood-brain barrier: This relates to a discovery of a cell surface protein, namely NgR2, that is implicated in regulation of blood-brain barrier (BBB). In addition, the invention relates methods for identifying agents that modulate BBB permeability. Furthermore, the invention relates to methods of delivering therapeutic agents to the central nervous system by... Agent: Wilson Sonsini Goodrich & Rosati

20080025960 - Detergents with stabilized enzyme systems: The present invention provides methods and compositions for the stabilization of oxidase enzymes during storage. In some preferred embodiments, the oxidase is a component of liquid detergent compositions. In some particularly preferred embodiments, the oxidase is stabilized by the addition of a reversible inhibitor of the oxidase to a liquid... Agent: Kamrin T. Macknight Danisco US Inc.

20080025962 - Remedy for alzheimer's disease: The present invention provides a prophylactic/therapeutic agent for Alzheimer's disease comprising a substance that inhibits the action of β-amyloid 1-40 to suppress vascular endothelial precursor cell differentiation and/or endothelial precursor differentiation from stem cells and/or a substance that promotes vascularization as an active ingredient. The present invention also provides a... Agent: Law Office Of Michael A. Sanzo, LLC

20080025963 - Compositions and methods for the treatment of cns injuries: The present invention is directed to a method of improving functional recovery following a central nervous system contusion injury. The method includes administering a therapeutically effective amount of glycosaminoglycan degrading enzyme. The glycosaminoglycan degrading enzyme may be dermatan sulfate or chondroitin sulfate degrading enzymes. The central nervous system contusion injury... Agent: Pepper Hamilton LLP

20080025964 - Modified ribonucleases: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in... Agent: Casimir Jones, S.c.

20080025965 - Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein levels: The invention features methods and compositions for reducing the serum C-reactive protein (CRP) level in a patient in need thereof, and for treating diseases and conditions associated with an increased serum CRP level. The invention also features methods and compositions for treating a patient diagnosed with, or at risk of... Agent: Clark & Elbing LLP

20080025973 - Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders: Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular... Agent: Alcon

20080025967 - Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in preventing and/or treating proliferative diseases caus: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080025968 - Methods and agents for immune modulation and methods for identifying immune modulators: Methods and agents for immune modulation and methods for identifying putative immune modulators are provided.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080025972 - Treating sex steriod responsive disorders: Sex steroid potentiated disorders including, prostate cancer and breast cancer, in a patient in need of treatment thereof, are treated with an amount of nitric oxide donating compound and/or nitrosoglutathione reductase inhibitor and/or cysteine binder different from that provided by nitric oxide donating compound effective to inhibit activation of steroid... Agent: Bacon & Thomas, PLLC

20080025969 - Treatment of neurodegenerative diseases by the use of gpr49: The invention relates to the use of a GPR49-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby s the GPR49-interacting molecule is preferably an inhibitor of GPR49 and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore... Agent: Clark & Elbing LLP

20080025974 - Human receptor proteins; related reagents and methods: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080025971 - Humanized anti-beta7 antagonists and uses therefor: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.... Agent: Genentech, Inc.

20080025970 - Treatment of atherosclerosis: Inhibitors of the adhesion of monocytes to oxidised low density lipoprotein or other lipid raft ligand for the therapy or prophylaxis of a condition involving monocyte adhesion to oxidised LDL or other lipid raft ligand, such as atherosclerosis, rheumatoid arthritis, multiple sclerosis or glomerulonephritis. An assay for identifying such inhibitors.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080025977 - Cytotoxicity mediation of cells evidencing surface expression of cd59: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.

20080025975 - Humanized antibodies against cd3: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific... Agent: Townsend And Townsend And Crew LLP

20080025976 - Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080025978 - High affinity ligand for p75 neurotrophin receptor: The present invention provides an isolated protein comprising a pro-domain of a proneurotrophin, methods for producing the protein, and pharmaceutical compositions containing the isolated protein. The invention also provides a nucleic acid molecule which encodes the protein and a vector containing the nucleic acid molecule. The present invention further provides... Agent: Hoffmann & Baron, LLP

20080025979 - Substance specific to human pd-1: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein... Agent: Sughrue-265550

20080025980 - Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.... Agent: Winston & Strawn LLP Patent Department

20080025981 - Cancer-linked genes as targets for chemotherapy: Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with methods for assaying for potential antitumor agents based on their modulation of the expression of these cancer-related genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions,... Agent: Alan J. Grant, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080025983 - Methods of screening based on the egf receptor crystal structure: This invention relates to the structure of members of the epidermal growth factor (EGF) receptor family and to receptor/ligand interactions. In particular, it relates to the field of using the EGF receptor family structure to select and screen for compounds that inhibit the formation of active receptor dimers.... Agent: Foley And Lardner LLP Suite 500

20080025982 - Uses of sperm membrane protein obf: The present invention yielded unique monoclonal antibodies that reacted specifically only to sperms after acrosome reaction, and the antigens (OBFs) recognized by the antibodies were identified. The antibodies were found to inhibit fusion between mouse sperms and eggs. Furthermore, OBF gene-knockout mice were created and analyzed to clarify the in... Agent: Fish & Richardson PC

20080025984 - Combination therapy comprising cloretazine: This invention provides a method for treating tumor in a subject comprising administering to the subject an effective amount of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. This invention also provides a method for inhibiting tumor cell growth comprising contacting the tumor cell with... Agent: Law Offices Of Albert Wai-kit Chan

20080025985 - Method of treating a pathological syndrome and a pharmaceutical agent: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms... Agent: Houston Eliseeva LLP - Ru

20080025986 - Methods of treating tnf-mediated disorders: The present invention provides methods of treating TNF-α-mediated disorders, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone or a pirfenidone analog and a second therapeutic agent that reduces TNF-α synthesis or that reduces TNF-α binding to a TNF receptor. The present invention further... Agent: Knobbe Martens Olson & Bear LLP

20080025987 - Release of bmp, bioactive agents and/or cells via a pump into a carrier matrix: A pump to deliver bone-growth factors to a carrier matrix within a patient. Pump can be internal or external. With external pumps, additional amounts of the same growth factor may be added, or the bioactive agent may be changed during the course of treatment. An external pump permits the use... Agent: Fox Rothschild, LLP

20080025988 - Monoclonal antibody and use thereof: p

20080025989 - Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders: Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical... Agent: Seattle Genetics, Inc.

20080025990 - Fully human antibodies directed against the human insulin-like growth factor-1 receptor: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the... Agent: Lucas & Mercanti, LLP

20080025992 - Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy: Methods are provided for the prevention and treatment of seizures and epilepsy. It is shown herein that leukocyte recruitment plays a key role in the pathogenesis of epilepsy. Treatment with an agent that inhibits leukocyte recruitment has therapeutic and preventative effects in blocking recurrent seizures and epilepsy.... Agent: Bozicevic, Field & Francis LLP

20080025991 - Use of aromatase inhibitors for treatment of ectopic pregnancy: Following a diagnosis of ectopic pregnancy, at least one aromatase inhibitor, is administered to a patient, either alone or in combination with other aromatase inhibitors or therapeutic agents or as an adjuvant to conservative surgical treatment, such as laparoscopy, to prevent the establishment and/or continuation of the ectopic pregnancy. In... Agent: Rohm & Monsanto

20080025993 - Method for refolding neisserial nspa protein: The present invention provides an isolated refolded NspA protein, and a method of preparing it.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080025994 - Methods and compositions for the treatment of pancreatitis: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.... Agent: Allergan, Inc.

20080025995 - Cross-placenta delivery system: The invention is directed to chimeral fusion proteins having an IgG1 antibody Fc portion and a lysosomal storage enzyme, particularly a Fc-GUS fusion protein useful in treating Sly's disease in an embryo or fetus. The invention is also directed to methods of treating in born errors of metabolism, particularly Sly's... Agent: Blackwell Sanders LLP

20080025996 - Methods and compositions comprising polycationic compounds: The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.... Agent: Mark B. Wilson Fulbright & Jaworski L.L.P.

20080025997 - Cysteine-rich region of respiratory syncytial virus and methods of use therefor: The invention features methods and compositions featuring an RSV Glycoprotein fragment for modulating an immune response in a subject.... Agent: Edwards Angell Palmer & Dodge LLP Client: Jhu

20080025998 - Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequence of chilamydia: The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a Chlamydia genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses. The ability of an... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080025999 - Yersinia species compositions: A method of protecting an animal from infections with pathogens originating from Yersinia comprising administering an isolated or recombinant YscF protein to the animal is disclosed. The isolated or recombinant YscF protein may be administered as a vaccine. An isolated or recombinant YscF protein capable of conferring protection to an... Agent: Traskbritt, PC

20080026000 - Hapten-carrier conjugates for treating and preventing nicotine addiction: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates... Agent: Foley And Lardner LLP Suite 500

20080026001 - Pharmaceutical composition from natural materials for regulating immunity, its preparation method and use: The present invention relates to a new pharmaceutical composition from natural materials belonging in traditional Chinese medicine and to its preparation method. Said new pharmaceutical composition comprises Astragalus root, Pleurotus fungi, Winnged Euonymus Twig and Mulberry Leaf. At first, astragalus root, Pleurotus fungi, Winnged Euonymus Twig and Mulberry Leaf are... Agent: Andrews Kurth LLP Intellectual Property Department

20080026002 - Regimens for immunisation with meningococcal conjugates: Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months.... Agent: Novartis Vaccines And Diagnostics Inc.

20080026003 - Methods for inhibiting pain: The invention provides methods for the treatment or prevention of pain. The invention also provides screening methods for determining whether a compound inhibits IL-1β activity in the central nervous system of a mammal.... Agent: Clark & Elbing LLP

20080026004 - Membrane virus host range mutations and their uses as vaccine substrates: The present invention is directed to genetically engineered, membrane-enveloped viruses with deletion mutations in the protein transmembrane domains. Also provided are viral vaccines based on the engineered viruses, methods of producing and using such vaccines.... Agent: David L Parker Fulbright & Jaworski

20080026005 - Multicopy-integration of heterologous genes and expression in methylobacterium: The integration of genes into methylobacterium, such as M. extorquens ATCC 55366 is disclosed, using a transposon system, preferably the mini-Tn7 transposon system, and under the control of a promoter, such as the strong methanol dehydrogenase promoter (PmxaF). Multicopy integration of genes of interest is also disclosed. The unique and... Agent: Cassan Maclean

20080026006 - Pharmaceutical composition useful for vaccines: A pharmaceutical composition including at least a mixture of at least one oil, at least one surfactant and an aqueous phase, itself including at least one active substance, the pharmaceutical composition not being in the form of an emulsion, but in the form of an oily isotrope.... Agent: Ip Group Of Dla Piper US LLP

20080026007 - Potentiation of the immune response: A method for stimulating proliferation of T-cells containing cytoplasmic post-prolyl dipeptidase activity; the method, in one aspect, involves contacting the T-cells with an organic compound at a concentration below 10−8M, wherein the compound is characterized in that: (a) it is capable of crossing the membrane of T-cells to enter the... Agent: Choate, Hall & Stewart LLP

20080026008 - Bacteriophage dna vaccine vector: Bacteriophages are used as a DNA delivery system for a vaccine against pathogens where glycosylation is critical to immunity.... Agent: Thomas A. O'rourke Bodner & O'rourke

20080026009 - Borrelia burgdorferi bacterin: A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080026010 - Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination: The present invention relates to a malaria vaccine for administration to a host comprising an attenuated malarial parasite with a gene which has been rendered non-functional, wherein the gene, when present in naturally occurring form, encodes a protein necessary for continued in vivo survival and proliferation of the parasite and... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080026011 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20080026012 - Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex: The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic peptides of cancer or infected cells. The claimed methods comprise the constructing of a nucleotide sequence encoding a secretable modified heat shock protein, expressing the sequence in... Agent: Nixon & Vanderhye, PC

20080026013 - Compositions containing quaternary ammonium compounds: This invention relates to compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, characterized in that the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which... Agent: Young & Thompson

20080026014 - Nasal stick for the application of medicaments and skin care substances: A stick for the topical or transmucosal application of a skin care or active agent onto and via the nasal mucosa, respectively, is provided, wherein the stick material contains a composition of at least one carrier substance and at least one skin care or active agent, which is capable of... Agent: Harness, Dickey & Pierce, P.L.C

20080026015 - Thermochromic compositions for skin applicaion: Thermochromatic dyes may be added to compositions to be applied to skin in order to indicate where the composition is applied. After application to the skin the composition will turn from colored to colorless in a short period of time as its temperature rises in response to the curing reaction... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20080026018 - Administration of coumarin, butylated hydroxyanisole and ethoxyquine for the treatment of canities: At least one compound selected from among coumarin and/or derivative thereof, butylated hydroxyanisole, ethoxyquine and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative conditions of the scalp, plant extracts having propigmenting activity and active agents that slow hair loss and/or promote... Agent: Buchanan, Ingersoll & Rooney PC

20080026019 - Administration of ellagic acid for the treatment of canities: At least one compound selected from among ellagic acid, its salts, its metal complexes, its monoether or polyether, monoacylated or polyacylated derivatives and its carbonate or carbamate derivatives deriving from hydroxyl groups and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative... Agent: Buchanan, Ingersoll & Rooney PC

20080026016 - Aqueous dispersions of low-water solubility or water-insoluble active substances and dry powders produced therefrom: The present invention relates to aqueous dispersions and dry powders prepared therefrom, comprising at least one active substance which is sparingly soluble, or insoluble, in water and rice starch as protective colloid.... Agent: Connolly Bove Lodge & Hutz, LLP

20080026020 - Cosmetic composition combining a c-glycoside derivative and an associative polymer: The present invention relates to a cosmetic and/or pharmaceutical composition, especially a dermatological composition, comprising, in a physiologically acceptable medium containing an aqueous medium, at least one C-glycoside derivative and at least one associative polymer.... Agent: Oliff & Berridge, PLC

20080026021 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080026017 - Novel dipeptides incorporating selenoamino acids with enhanced bioavailability- synthesis, pharmaceutical and cosmeceutical applications thereof: Disclosed is a novel synthetic method for isomeric peptides through an appropriate linkage of L-selenomethionine or Se-Methyl-L-selenocysteine with L-glutamic acid. The novel synthetic method produces isomeric peptides of L-selenomethionine or Se-Methyl-L-selenocysteine that exhibit (i) enhanced water solubility; (ii) enhanced rate of dissolution in water; (iii) enhanced bioavailability; (iv) excellent vascular... Agent: Sabinsa Corporation

20080026022 - Process for the preparation of stable polymer concentrates: Process for preparing stable polymer concentrates, wherein acryloyldimethyltaurine and/or acryloyldimethyltaurate are free-radically polymerized with at least one further component in the presence of a polymerization medium, a higher-boiling solvent or solvent mixture is added to the resulting reaction product or reaction mixture, and the lower-boiling polymerization medium is removed, optionally... Agent: Clariant Corporation Intellectual Property Department

20080026023 - Textile material for management of skin health complications associated with skin folds, and its method of use: A textile material for management of skin health complications associated with skin folds includes a disposable textile of selected dimensions, impregnated with a selected concentration of an antimicrobial silver complex. The disposable textile is designed to be placed within a skin fold for management of skin health complications associated therewith.... Agent: Coloplast Corp. I.p. Department, U.s. Operations

20080026024 - Insect pest behavioral disturbance inducer, functional fiber, functional fabric and functional fiber product: The invention is an insect pest behavioral disturbance inducer which comprises an organic ester compound having a vapor pressure of 10−3 Pa (25° C.) order or less as an active ingredient, a functional fiber and a functional fabric, which hold aforementioned insect pest behavioral disturbance inducer, and a functional fiber... Agent: Sughrue-265550

20080026025 - Broad spectrum antimicrobial purification materials and methods for purifying fluids: Purification materials with broad spectrum antimicrobial properties and methods and devices for fluid treatment utilizing said materials are provided. The purification materials include biguanide hydrates and bases. A particular composition includes chlorhexidine dihydrate with the chemical formula (C22H30N10Cl2.1.3 H2O), which is useful in water purification applications.... Agent: Sutherland Asbill & Brennan LLP

20080026028 - Antimicrobial silver halide composition: This invention relates to a composition comprising at least 50% water, silver halide particles and a hydrophilic polymer, wherein the composition does not substantially gel or solidify at 25 degrees C.; is substantially free of organic solvents; and exhibits antimicrobial activity upon drying. The composition may further comprise a hydrophobic... Agent: Andrew J. Anderson Patent Legal Staff

20080026027 - Hybrid anti-fouling coating compositions and methods for preventing the fouling of surfaces subjected to a marine environment: The present invention relates to a coating composition including a sol-gel matrix and a dendrimeric organochalcogeno derivative and a system including the coating composition and a substrate. The present invention also relates to a method of preventing fouling of surfaces subjected to a marine environment.... Agent: Nixon Peabody LLP - Patent Group

20080026026 - Removable antimicrobial coating compositions and methods of use: This invention relates to a method for controlling microorganisms comprising coating a surface with a removable, antimicrobial film-forming composition.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080026029 - Energy-activated compositions for controlled sustained release of a gas: A composition for energy-controlled generation and release of at least one gas, which includes an energy-activated catalyst capable of being activated by electromagnetic energy, and a solid or a liquid containing anions capable of being oxidized by the activated catalyst or reacted with species generated during activation of the catalyst... Agent: Senniger Powers

20080026032 - Composite implants for promoting bone regeneration and augmentation and methods for their preparation and use: Collagen based matrices cross-linked by a reducing sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two layers including reducing sugar cross-linked collagen matrices of different densities. The composite matrices may be used in bone regeneration and/or augmentation applications. Scaffolds including glycated... Agent: Daniel J Swirsky

20080026030 - Corneal epithelial sheet and process for producing the same: A corneal epithelial sheet having a cell layer similar to the anterior epithelium of cornea. A corneal epithelial sheet is obtained through the step (a) of separately preparing a first cell being a self cell and a second cell whose origin is different from that of the first cell, the... Agent: Kratz, Quintos & Hanson, LLP

20080026031 - Implantable polymeric device for sustained release of buprenorphine: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric... Agent: Morrison & Foerster LLP

20080026033 - Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis: The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.... Agent: Howrey LLP

20080026034 - Therapeutic agent elution control process: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20080026035 - Method of treating atrophic vaginitis: The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.... Agent: Baker Botts L.L.P.

20080026036 - Method of feeding a ruminant: A method of feeding ruminants, the method including feeding a ruminant a fluid animal feed during a feeding period, the fluid animal feed including an animal feed component and the ruminant consuming greater than about 1.25 pounds of the animal feed component per day, based on the dry weight of... Agent: Law Office Of Phillip F. Fox

20080026037 - Compositions comprising strontium and vitamin d and uses thereof: The invention relates to the finding that very favorable pharmacokinetic characters are obtained by combining two strontium salts in one pharmaceutical composition. The present invention relates in one aspect to a pharmaceutical composition comprising at least two strontium salts for use as a medicament, and in particular for the treatment... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080026038 - No laxation, low flatulence bulking system: A no-laxation, low flatulence bulking system and a method for preparation of same is disclosed. Gelatin, pectins and gellan gum are combined to form a dry-blended mixture. A second set of ingredients comprising at least erithritol is combined. A first liquid mixture comprising modified polydextrose and water is formed. The... Agent: Fulbright & Jaworski L.l.p

20080026040 - Active agent-releasing dosage forms: The present invention provides pharmaceutical compositions. In one aspect, a pharmaceutical composition is provided having a plurality of polymeric film layers heat sealed together as a multilayer structure and having an active agent dispersed within the multilayer structure. The multilayer structure is configured to release the active agent upon administration... Agent: Hewlett Packard Company

20080026039 - Benzoyl peroxide pads and formulations therefor: Pharmaceutical delivery systems suitable for topical administration including benzoyl peroxide. In a particular aspect, these pharmaceutical delivery systems comprise at least one pad and a drug composition comprising benzoyl peroxide absorbed onto the pad. These compositions are used for topical medical applications, particularly to treat various skin disorders.... Agent: Nath & Associates

20080026041 - Non-woven media incorporating ultrafine or nanosize powders: The invention is a fibrous structure for fluid streams that is a mixture of nano alumina fibers and second fibers arranged in a matrix to create asymmetrical pores and to which fine, ultrafine, or nanosize particles such as powdered activated carbon are attached without the use of binders. The fibrous... Agent: Cohen & Grigsby, P.C.

20080026042 - Preoperative treatment of post operative pain: A method of treating postoperative pain in a patient undergoing a surgery id described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent... Agent: Darby & Darby P.C.

20080026043 - Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer: The invention relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer and is anchored in the backing layer by siliconization.... Agent: Cathy R. Moore Propat

20080026045 - Combination chemotherapy comprising a gemcitabine and a liposomal platium complex: The present invention relates to methods for treating cancer comprising administering a combination of gemcitabine and a liposomal platinum complex, pharmaceutical compositions comprising gemcitabine and a liposomal platinum complex, and kits comprising unit dosage forms of gemcitabine and a liposomal platinum complex.... Agent: Jones Day

20080026044 - Combination chemotherapy comprising capecitabine and a liposomal platinum complex: The present invention relates to methods for treating cancer comprising administering a combination of capecitabine and a liposomal platinum complex, pharmaceutical compositions comprising capecitabine and a liposomal platinum complex, and kits comprising unit dosage forms of capecitabine and a liposomal platinum complex.... Agent: Jones Day

20080026046 - Stable aqueous g-csf conatining compositions: The invention relates to highly stable aqueous G-CSF-containing compositions that contain succinate and/or tartrate as the buffer substances. The invention further concerns lyophilisates and powders that are obtainable from such compositions, and to pharmaceutical kits containing such lyophilisates and powders.... Agent: Catalyst Law Group, Apc

20080026047 - Cancer detection reagents and uses in pathology and diagnostics and cancer cell death: Cancer detection reagents have been identified through comparison of cancer mRNAs with the transcriptome of healthy cells. These cancer detection reagents may be used for a variety of purposes including diagnostics and targeted destruction of cancer cells. In diagnostic applications, peripheral blood or other tissue samples from a subject may... Agent: Baker Botts L.L.P. Patent Department

20080026049 - Liposomal compositions for parenteral delivery of agents: The invention provides methods and compositions for loading an agent onto a liposome for parenteral delivery. The methods are suitable for the loading of poorly soluble agents onto liposomes.... Agent: Bereskin And Parr

20080026048 - Reovirus for the treatment of cellular proliferative disorders: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the... Agent: Fish & Richardson P.C.

20080026050 - Solid dose formulations of a thrombin receptor antagonist: t

20080026051 - Pharmaceutical form having a two-layer separating layer: A pharmaceutical form, contains an active compound-containing core, which is covered with a coating layer of a gastric juice-resistant, intestinal juice-soluble (meth)acrylate copolymer, a separating layer situated between said core and said coating layer, the separating layer containing a film-forming water-soluble polymer, wherein the separating layer contains at least two... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080026052 - Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats: The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.... Agent: Bell, Boyd & Lloyd, LLP

20080026053 - Capsule containing granular pharmaceutical compositions: A capsule for oral administration to a human subject. The capsule comprises at least two different pharmaceutical compositions in granular form. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.... Agent: Greenblum & Bernstein, P.L.C

20080026054 - Novel anelgesic combination: The invention discloses a method of administering a pharmaceutical combination comprising an NSAID and a slow release tramadol to a mammal in need of thereof. This invention further discloses an analgesic combination comprising an NSIAD and a slow release tramadol for treating pain and pain related conditions.... Agent: Ramesh Sesha

20080026055 - Chewable tablet containing phenylephrine: A chewable pharmaceutical composition comprising phenylephrine, artificial sweetener, and a substantially aldehyde-free matrix is provided. The composition has phenylephrine stability suitable for a typical commercial product with a two year shelf life. A method of manufacture of the composition and a method of use are also provided.... Agent: Wyeth Patent Law Group

20080026056 - Antibiotic-based pharmaceutical formulation in microcapsular form: c

20080026058 - Methods for treating and preventing mucositis: Methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy, are disclosed herein. More specifically, disclosed herein is the administration of a therapeutically effective amount of at least one of an anthocyanoside, a proanthocyanidin, or an extract... Agent: Jones Day

20080026057 - Process for the preparation of a solid, orally administrable pharmaceutical composition: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, the pharmaceutical composition resulting from this process, and its use for the prophylaxis and/or treatment of thromboembolic diseases.... Agent: Jeffrey M. Greenman

20080026059 - Methods of reducing degradant formation in pharmaceutical compositions of varenicline: The invention relates to methods for reducing degradant formation in pharmaceutical dosage forms of varenicline, which are useful for aiding smoking cessation and which have good storage stability. In particular, the present invention relates to methods for preparing formulations of varenicline wherein the dosage forms that are produced therefrom generate... Agent: Pfizer Inc Steve T. Zelson

20080026060 - Controlled-release pharmaceutical tablets: Controlled-release tablets exhibiting excellent storage stability are achieved by granulating a pharmaceutically active agent with a hydroxyalkylcelluose, blending the resulting granules with an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which may be optionally coated, such as... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080026061 - Crystalline n-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide: Provided herein are polymorphs of N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide and pharmaceutical compositions thereof. Also provided are methods of treatment of endothelin-mediated disorders by administering a polymorph N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide or pharmaceutical compositions thereof.... Agent: Jones Day

20080026062 - Pharmaceutical compositions including nano-sized active agent: The present invention is directed to a particulate pharmaceutical composition. The particulate pharmaceutical composition can comprise a water-soluble or partially water-soluble polymer matrix; and a plurality of nano-sized particles of active agent which are sparingly water-soluble to water-insoluble dispersed in the water-soluble or partially water-soluble polymer matrix. The particulate pharmaceutical... Agent: Hewlett Packard Company

20080026064 - Cell-polymer fiber compositions and uses thereof: The present invention relates to compositions comprising complexes of human cells and polymer fibers and methods of their use for therapeutic purposes. Methods of making such compositions are also provided. The present invention encompasses compositions comprising poly-β-1→4-N-acetylglucosamine polymers and stored platelets and their use for promoting wound healing and achieving... Agent: Jones Day

20080026063 - Composition containing reduced coenzyme q10 and production method thereof: The present invention provides a particulate composition wherein an oil component containing reduced coenzyme Q10 is polydispersed forming a domain in a matrix containing a water-soluble excipient, which simultaneously shows high oxidative stability and high oral absorbability, a production method thereof, and a stabilizing method thereof. It also provides a... Agent: Sughrue Mion, PLLC

20080026066 - Liquids containing suspended glass particles: Present proposals to use perfluorocarbons as a medium to suspend glass particles presents the problem of aggregation of the particles within the suspending medium. Overcoming this problem requires careful particle sizing and density matching techniques. An additional disadvantage of the large scale use of perfluorocarbons is their contribution to global... Agent: Brooks Kushman P.C./fgtl

20080026069 - Particles: Particles and related methods are disclosed.... Agent: Fish & Richardson PC

20080026065 - Powdered compositions of sensitive active materials in an at least partially amorphous state: The invention provides a powdered formulation which is a freeze-dried mixture of a sensitive active material and an excipient containing: 0.1-50% by wt of the sensitive active material, 50-99.99% by wt of the excipient, wherein at least 0.1% by wt of the mixture is an amorphous state; the formulation has... Agent: Hoffmann & Baron, LLP

20080026067 - Method for increasing specific surface area of slightly soluble drug: The preparation method of the powder of which dissolution rate improves is characterized by including of the process that slightly soluble drug having acidic group (e.g., 3-(5-{2-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]ethoxy}-3,4-dihydronaphthalen-1-yl)propanoic acid etc.) is made to metal salt solution and is neutralized to precipitate. By the method of the present invention, since a powder... Agent: Sughrue-265550

20080026070 - Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications: e

20080026068 - Pulmonary delivery of spherical insulin microparticles: Compositions of spherical insulin particles having improved pulmonary application potentials and methods of forming and using these compositions are disclosed in the present application. In one clinical trial with 30 healthy male human subjects, no coughing was observed upon a single pulmonary administration of the spherical insulin particles at an... Agent: Baxter Healthcare Corporation

20080026071 - Microparticles for delivery of heterologous nucleic acids: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. Also provided are microparticles... Agent: Lee, Helen Novartis Vaccines And Diagnostics, Inc.

20080026072 - Antimicrobial carbohydrates and methods of using same: Compositions useful for inhibiting the growth of bacteria, including bacteria that can cause gastric ulcers, are provided. In addition, transgenic organism that can produce such compositions are provided. Methods of using the compositions to treat or prevent gastric ulcers in a subject, including a human subject, also are provided.... Agent: Dla Piper US LLP

20080026073 - Method and composition for lithium additive in treatment of glutamate toxicity: Treatment of glutamate toxicity is accomplished using Lithium or a composition of Lithium and a botanical extract. The composition is administered using conventional techniques to increase the survival of ganglion cells exposed to glutamate toxicity resulting from ischemic events. In exemplary embodiments, the botanical extract is St. Johns Wort, Tian... Agent: Felix L. Fischer, Attorney At Law

20080026074 - Method of short term skin wrinkles correction using strontium divalent ion: A method for the treatment of skin damage using strontium divalent ion in a dermatologically acceptable carrier is provided, usually an essential oil distillate. The compositions are applied topically to improve appearance of skin damaged by sun or by natural aging. The compositions may additionally include antioxidant molecules such as... Agent: Hannah Sivak

20080026075 - Constitutional function-improving agents: Health function-improving agents, such as an immunological function-improving agent, an antioxidation function-improving agent, a exercise function-improving agent and a liver function-improving agent, comprising, as an effective ingredient, a δ-amino acid, a derivative thereof or a salt thereof... Agent: Sughrue-265550

20080026076 - Quercetin supplementation to treat hypertension: A nutritional supplement for improving cardiovascular health via aiding in preventing, slowing the progression of and/or treating hypertension, the supplement comprising quercetin; and a method for aiding in preventing, slowing the progression of and/or treating hypertension are described.... Agent: Needle & Rosenberg, P.C.

20080026077 - Methods and compositions of gene delivery agents for systemic and local therapy: A method is provided for the delivery of a therapeutic to epithelial cells through the use of a bile acid conjugated to a peptide, the peptide being ionically charged at physiological pH. The complex is well suited for oral and other forms of therapeutic administration of therapeutic drugs known in... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080026078 - Nasal composition: A nasal spray solution for use as a nasal spray and methods of using the solution are disclosed. The nasal spray solution moisturizes nasal passages and alleviates nasal dryness. The solution includes a hypotonic saline solution, wherein the saline solution is hypotonic with respect to cells of the nasal mucosa... Agent: Hahn Loeser & Parks, LLP

20080026079 - Calcium aluminosilicate pharmaceutical: A composition and method of treating symptoms of diarrhea that utilize administering an effective amount of an isolated calcium aluminosilicate anti-diarrheal (“CASAD”), wherein the isolated CASAD is substantially free from T4-dioxin and toxic heavy metal contamination, waiting a period of time; and repeating the administration of the composition until the... Agent: Jackson Walker LLP

20080026080 - Method for manufacturing calcium gluconolactate compositions processes and uses: A method to manufacture calcium gluconolactate as a single molecule, compositions formed thereby, and uses therefor are disclosed and described. In one embodiment, a method of manufacturing calcium gluconolactate by reacting a gluconic acid reaction or an equivalent thereof, such as glucono delta lactone with lactic acid in the presence... Agent: Thorpe North & Western, LLP.

20080026081 - Methods of treatment using (+)-isopropyl 2-ethoxyethyl-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate: The present invention relates to methods of treatment using the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, as a sole active agent or in combination with other pharmacological agents.... Agent: Millen, White, Zelano & Branigan

20080026082 - Erectyle disfunction phyto-nutraceutical synergistic composition: A Phytoceutical composition for the prevention and treatment of erectile dysfunction is provided. A specific combination of extracts of plants and nutraceuticals is based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combination has synergistic effects, with minimal side effects.... Agent: Jose Olalde Rangel

20080026084 - Method and composition for management of weight and blood sugar: A method for the identification of a composition useful in the treatment of an overweight or obese person to reduce the person's body mass index is provided which comprises obtaining an extract of an ethnobotanical plant, and evaluating the activity of the extract in an assay. A composition is described... Agent: Ward And Smith, P.A.

20080026083 - Antimicrobial and pesticidal compositions and methods comprising reduced monoterpene oil extracted from myrtaceae: The invention comprises compositions and methods for the treatment or prophylaxis of a microbial, fungal, or mold infection in an animal, comprising the administration of a composition derived from the essential oil of a Myrtaceae plant, wherein at least about 85% of the monoterpene content of the oil has been... Agent: Rader, Fishman & Grauer PLLC

20080026085 - Herbal mixture extract of rehmanniae radix preparata and acanthopanacis cortex and a composition comprising the same for prevention and treatment of osteoporosis: The present invention relates to a herbal mixture extract of Rehmanniae Radix Preparata and Acanthopanacis Cortex and a composition comprising the same for the prevention and treatment of osteoporosis. The herbal mixture extract of the present invention enhances the expression of osteoprotegerin (OPG) in osteoblasts and effectively inhibits the generation... Agent: Joseph Hyosuk Kim, Ph.d. Jhk Law

20080026086 - Synergistic neuroprotective, combinations of flavanols, hydroxystilbenes, flavanones, flavones, flavonols, proanthocyanidins and anthocyanidins: A synthetic composition is provided comprising (a) one or more compounds selected from the group consisting of flavanols and hydroxystilbenes; and (b) one or more compounds selected from the group consisting of flavanones, flavones, flavonols, proanthocyanidins and anthocyanidins. Also provided is a method of reducing neuronal degeneration in an individual... Agent: Unilever Intellectual Property Group

20080026087 - Litchi sinensis extracts containing oligomeric proanthocyanidins and processes of making thereof: A botanic extract of Litchi sinensis containing, based on active substance content, at least 15% by weight of an oligomeric proanthocyanidin of the OPC A2 type is disclosed. Processes of making such extracts containing at least 15% by weight of OPC A2 are also disclosed.... Agent: Cognis Corporation Patent Department

20080026088 - Reduced isoalpha acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on reduced isoalpha acids, commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080019907 - Optical imaging contrast agents: The invention provides contrast agents for optical imaging of vulnerable atherosclerotic plaque in patients. The contrast agents may be used in diagnosis of vulnerable atherosclerotic plaque, for follow up of progress in disease development, for follow up of treatment of vulnerable atherosclerotic plaque and for surgical guidance. Further, the invention... Agent: Ge Healthcare, Inc.

20080019909 - Modulation of programmed necrosis: Methods related to modulating programmed necrosis are described. The methods relate to modulation of proteins involved in programmed necrosis, e.g., tumor necrosis factor receptor (2) (TNFR-2), tumor necrosis factor receptor (1) (TNFR-1), and receptor-interacting protein (RIP).... Agent: Fish & Richardson P.C.

20080019923 - Gas bubble-generating agent: This invention provides a gas bubble-generating agent that can be used as a contrast medium or a blocking agent in vivo. Such gas bubble-generating agent is produced by a method for producing a gas bubble-generating agent comprising the following steps of: (a) preparing a mixed solution of an amphiphilic substance,... Agent: Mattingly, Stanger, Malur & Brundidge, P.C.

20080019932 - Color cosmetic compositions: A color cosmetic composition comprising at least one silicone film forming polymer, at least one pigment, and at least one dispersant that aids in dispersion of the pigment and silicone film forming polymer in the composition.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20080019935 - Conditioning composition comprising silicone agent for ease-to-rinse feel and/or clean feel: Disclose